Premium
Lisdexamfetamine Dimesylate Effects on Binge Eating Behaviour and Obsessive–Compulsive and Impulsive Features in Adults with Binge Eating Disorder
Author(s) -
McElroy Susan L.,
Mitchell James E.,
Wilfley Denise,
Gasior Maria,
FerreiraCornwell M. Celeste,
McKay Michael,
Wang Jiang,
Whitaker Timothy,
Hudson James I.
Publication year - 2016
Publication title -
european eating disorders review
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.511
H-Index - 67
eISSN - 1099-0968
pISSN - 1072-4133
DOI - 10.1002/erv.2418
Subject(s) - binge eating , binge eating disorder , disinhibition , psychology , barratt impulsiveness scale , placebo , bulimia nervosa , psychiatry , impulsivity , eating disorders , clinical psychology , medicine , alternative medicine , pathology
In a published 11‐week, placebo‐controlled trial, 50 and 70 mg/d lisdexamfetamine dimesylate (LDX), but not 30 mg/d LDX, significantly reduced binge eating days (primary endpoint) in adults with binge eating disorder (BED). This report provides descriptions of LDX effects on secondary endpoints (Binge Eating Scale [BES]; Three‐Factor Eating Questionnaire [TFEQ]; Yale–Brown Obsessive Compulsive Scale modified for Binge Eating [Y‐BOCS‐BE]; and the Barratt Impulsiveness Scale, version 11 [BIS‐11]) from that study. Week 11 least squares mean treatment differences favoured all LDX doses over placebo on the BES ( p ≤ 0.03), TFEQ Disinhibition and Hunger subscales (all p < 0.05), and Y‐BOCS‐BE total, obsessive, and compulsive scales (all p ≤ 0.02) and on BIS‐11 total score at 70 mg/d LDX ( p = 0.015) and the TFEQ Cognitive Restraint subscale at 30 and 70 mg/d LDX (both p <0.05). These findings indicate that LDX decreased global binge eating severity and obsessive–compulsive and impulsive features of BED in addition to binge eating days. Copyright © 2015 John Wiley & Sons, Ltd and Eating Disorders Association.